TKTL1 Expression and Survival in Rectal Cancer
Author Information
Author(s): Juliana Schwaab, Karoline Horisberger, Philipp Ströbel, Beatrice Bohn, Deniz Gencer, Georg Kähler, Peter Kienle, Stefan Post, Frederik Wenz, Wolf-Karsten Hofmann, Ralf-Dieter Hofheinz, Philipp Erben
Primary Institution: Universitätsmedizin Mannheim
Hypothesis
Does the expression of TKTL1 predict disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy?
Conclusion
High TKTL1 expression correlates with poor prognosis in terms of 3-year disease-free survival in patients with locally advanced rectal cancer treated with intensified neoadjuvant chemoradiotherapy.
Supporting Evidence
- Patients with high TKTL1 expression had a 39% disease-free survival rate compared to 87% for those with low expression.
- High TKTL1 expression was significantly correlated with the development of metastases.
- VEGFR-1 and VEGFR-2 expression levels were significantly higher in tumor tissue compared to normal tissue.
Takeaway
This study found that patients with high levels of a specific gene called TKTL1 had a lower chance of being cancer-free after treatment for rectal cancer.
Methodology
Patients' tumor and normal tissue were analyzed using quantitative PCR to measure gene expression levels.
Limitations
The study had a relatively small sample size, which may limit the generalizability of the findings.
Participant Demographics
33 patients (23 male, 10 female; median age 61 years)
Statistical Information
P-Value
0.01
Confidence Interval
0.05-0.6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website